Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
Human leukocyte antigen (HLA)-B7/beta-2 microglobulin plasmid DNA/lipid complex, otherwise known as Allovectin-7 (Vical, Inc., San Diego, CA, USA), has been developed as a non-viral gene delivery product. After multiple laboratory and human trials, it appears that the concept of gene transfer has established itself as a clinical reality. While the manifestations of the gene transfer have not been as dramatic as one might have hoped, HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex appears to be a promising agent with an extremely safe toxicity profile. Ongoing trials are further investigating potential clinical uses of Allovectin-7.
Bergen
Michael
M
University of Colorado Cancer Center, Anschutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, Colorado 80010, USA. Michael.Bergen@uchsc.edu
Chen
Robert
R
Gonzalez
Rene
R
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004247:DNA / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004274:DNA, Recombinant; D015793:HLA-B7 Antigen / Q000235:genetics*; D006801:Humans; D008055:Lipids / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008081:Liposomes; D008545:Melanoma / Q000628:therapy*; D009362:Neoplasm Metastasis; D010957:Plasmids / Q000235:genetics*; D001613:beta 2-Microglobulin / Q000235:genetics*
C096492:Allovectin-7; D004274:DNA, Recombinant; D015793:HLA-B7 Antigen; D008055:Lipids; D008081:Liposomes; D001613:beta 2-Microglobulin; D004247:DNA